Advertisement

Spine Surgery pp 385-399 | Cite as

Primary Malignant Tumors

  • Marcus RickertEmail author
  • M. Rauschmann
Chapter

Abstract

Primary malignant bone tumors of the spine (i.e., vertebral sarcomas, not plasmocytomas) are very rare entities and account for only 5–10% of all primary malignant bone tumors of the entire skeleton.

References

  1. 1.
    Kelley SP, Ashford RU, Rao AS, Dickson RA. Primary bone tumours of the spine: a 42-year survey from the Leeds Regional Bone Tumour Registry. Eur Spine J. 2007;16:405–9.CrossRefGoogle Scholar
  2. 2.
    Moore DD. Haydon RC Ewing’s sarcoma of bone. Cancer Treat Res. 2014;162:93–115.CrossRefGoogle Scholar
  3. 3.
    Ewing J. Diffuse endothelioma of bone. Proc NY Pathol Soc. 1921;21:17–24.Google Scholar
  4. 4.
    Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol. 2008;30(6):425–30.CrossRefGoogle Scholar
  5. 5.
    Freyschmidt J, Jundt G, Ostertag H. Knochentumoren: Klinik, Radiologie, Pathologie. Berlin/Heidelberg/New York: Springer; 2003.Google Scholar
  6. 6.
    Kim HJ, McLawhorn AS, Goldstein MJ, Boland PJ. Malignant osseous tumors of the pediatric spine. J Am Acad Orthop Surg. 2012;20(10):646–56.PubMedGoogle Scholar
  7. 7.
    Caudill JS, Arndt CA. Diagnosis and management of bone malignancy in adolescence. Adolesc Med State Art Rev. 2007;18(1):62–78. ix.PubMedGoogle Scholar
  8. 8.
    West DC. Ewing sarcoma family of tumors. Curr Opin Oncol. 2000;12(4):323–9.CrossRefGoogle Scholar
  9. 9.
    Schaser KD, Melcher I, Druschel C, Tsitsilonis S, Disch AC. Surgical management of thoracolumbar spinal sarcoma. Orthopade. 2012;41(8):659–73.CrossRefGoogle Scholar
  10. 10.
    Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184–92.  https://doi.org/10.1016/S1470-2045(09)70286-4.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoffmann C, Ahrens S, Dunst J, et al. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer. 1999;85(4):869–77.CrossRefGoogle Scholar
  12. 12.
    Frisch S, Timmermann B. The evolving role of proton beam therapy for sarcomas. Clin Oncol (R Coll Radiol). 2017;29(8):500–6.CrossRefGoogle Scholar
  13. 13.
    Flanagan AMYT. Chordoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue andbone. Lyon: IARC Press; 2013. p. S328–9.Google Scholar
  14. 14.
    McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM. Chordoma: incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control. 2001;12:1–11.CrossRefGoogle Scholar
  15. 15.
    Lauer SR, Edgar MA, Gardner JM, Sebastian A, Weiss SW. Soft tissue chordomas: a clinicopathologic analysis of 11 cases. Am J Surg Pathol. 2013;37:719–26.CrossRefGoogle Scholar
  16. 16.
    Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer. 2000;88:2122–34.CrossRefGoogle Scholar
  17. 17.
    Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71–83.CrossRefGoogle Scholar
  18. 18.
    Stacchiotti S, Casali PG, Vullo SL. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol. 2010;17:211–9.CrossRefGoogle Scholar
  19. 19.
    Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13:e69–76.9.CrossRefGoogle Scholar
  20. 20.
    Rotondo RL, et al. High-dose proton-based radiation therapy in the management of spine chordomas: Outcomes and clinicopathological prognostic factors. J Neurosurg Spine. 2015;23:788–97.CrossRefGoogle Scholar
  21. 21.
    De Amorim Bernstein K, DeLaney T. Chordomas and chondrosarcomas-the role of radiation therapy. J Surg Oncol. 2016;114(5):564–9.  https://doi.org/10.1002/jso.24368. Epub 2016 Oct 19.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen YL, et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976). 2013;38:E930–6.CrossRefGoogle Scholar
  23. 23.
    Imai R, et al. Carbon ion radiotherapy for unresectable sacral chordomas. Clin Cancer Res. 2004;10:5741–6.CrossRefGoogle Scholar
  24. 24.
    Varga PP, Szövérfi Z, Fisher CG, Boriani S, Gokaslan ZL, Dekutoski MB, Chou D, Quraishi NA, Reynolds JJ, Luzzati A, Williams R, Fehlings MG, Germscheid NM, Lazary A, Rhines LD. Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J. 2015;24(5):1092–101.CrossRefGoogle Scholar
  25. 25.
    Stacchiotti S, Casali PG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. 2011;13:323–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Orthopaedic University Hospital Friedrichsheim gGmbH FrankfurtFrankfurt am MainGermany
  2. 2.Department of Spine SurgerySana Klinikum OffenbachOffenbachGermany

Personalised recommendations